4 results
To demonstrate the superior clinical efficacy of GelrinC on pain and function for the treatment of symptomatic focal articular cartilage defects of the femoral condyle in comparison to microfracture historical control at 24 months post-surgery.
To assess the impact of six IV infusions of 3, 6, or 12 mg/kg of CER-001 or placebo, given at weekly intervals, on atherosclerotic plaque volume, as measured by coronary IVUS.
The objective of this study is to evaluate efficacy and the safety of GelrinC® implant microfracture in the treatment of patients with symptomatic articular cartilage defect(s) of the femoral condyle.
To assess the rate of complete response (CR) in Grades III and IV SR-aGVHD participants on Day 28 postrandomization.